News

Releases

25. November, 2021

Exercise warrants of series TO1 before 14 Dec

In connection with the Company’s IPO in November/December 2020, Cessatech issued units (shares and...

Read more

Releases

2. November, 2021

First US patent covering CT001

The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11.160.799...

Read more

Media

23. September, 2021

#FEMSNABBA…

https://borsvarlden.com/artiklar/Fem-fr%C3%A5gor-till-Jes-Trygved?fbclid=IwAR0sa-omHrXpxrvnQd87xFDRDWZzVQQsIEr6VH9aY7S8BkLbXNzhL6AnShI

Read more

Releases

20. August, 2021

Cessatech reports first patient dosed in pharmacokinetic trial in children of lead product candidate

Clinical trial 0206 will investigate the pharmacokinetics  in children aged 1-17 undergoing elective surgical...

Read more

Releases

19. August, 2021

Second quarter report Q2-2021 – planning for the pivotal trials

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...

Read more

Releases

29. June, 2021

Cessatech announces new Chairman of the Board – getting ready for the pivotal studies

  The Board of Directors has appointed Adam Steensberg as new Chairman of the...

Read more

Releases

31. May, 2021

Last subject dosed in bioavailability trial 0204 of lead product candidate

Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports...

Read more

Releases

14. May, 2021

Cessatech A/S is awarded IPO of the year 2020 by independent editorial Affärsvärlden

Among the 26 micro-companies, the IPO guide’s reviewers found an average of 2.9 flags....

Read more

Releases

19. April, 2021

First quarter report Q1-2021 – ‘one down, two to go’ of the major milestones of 2021

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...

Read more

Media

26. March, 2021

Cessatech utvecklar nästa generations smärtlindring för barn

Cessatech är ett danskt läkemedelsbolag specialiserat på forskning och utveckling av smärtstillande nässpray som...

Read more

Releases

24. March, 2021

Cessatech reports first subject dosed in bioavailability trial of lead product candidate

Clinical trial 0204 in healthy volunteers will investigate the absolute bioavailability of CT001. Primary...

Read more

Releases

9. March, 2021

Cessatech A/S is awarded Best Medical Treatment IPO Nordics in 2020 by independent editorial

CFI.co – a journal and online resource reporting on business, economics and finance –...

Read more

Stay up to date!

Subscribe and get notified on Cessatech's latest news.